

January 21, 2020

**Physician Administered Drug
Prior Authorization Criteria for
Evenity™**

Version 1, 1-21-20

Evenity™ Romosozumab-aqqg
Evenity™ is a sclerostin inhibitor.

Indications¹:

Evenity™ is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Criteria for Approval^{1,2}:

1. Member

- a. Has osteoporosis, defined as having BMD T-scores of -2.5 or less at the lumbar spine or femoral neck **AND**
- b. Has a high risk of fracture defined as a history of osteoporotic fracture, or multiple risk factors for fracture.

AND

2. Member has failed adequate trials of alendronate, Forteo, and Prolia. An adequate trial is 180 days. Failure is worsening of BMD despite adherence. If the member cannot tolerate an oral bisphosphonate, an IV one must be tried and vice versa.

AND

3. **All** of the following:

- Member is a postmenopausal woman
- Member does not have pre-existing hypocalcemia¹; and
- Member has discontinued use of tobacco products²; and

- Member completes weight bearing exercise daily²; and
- Member takes calcium at about 1200 mg/day in divided doses and Vitamin D at about 800 IU daily^{1,2} and **any deficiencies have been corrected**; and
- Member has not previously used romosozumab; and
- The side effects have been discussed with the patient and the patient agrees to submit to treatment.

Quantity Limit:

Limited to 12 monthly doses.

Criteria for Renewal Authorization Approval:

- Authorization beyond 12 months is not indicated.

References:

1. Evenity™ [package insert] Thousand Oaks, CA; Amgen Inc.; 12/2019, (Accessed January 19, 2020).
2. [Rosen, H. Overview of the management of osteoporosis in postmenopausal women. Mulder, Jean, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com> \(Accessed on January 19, 2020\)](#)
3. Lexicomp Online®, Lexi-Drugs®, Hudson, Ohio: Lexi-Comp, Inc.; January 19, 2020